Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CR011-vcMMAE · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| CR011-vcMMAE | DRUG | administered as an intravenous infusion on Day 1 of a 21 day cycle. |
Main Inclusion Criteria: * Females with confirmed breast cancer * Age ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2 * Locally advanced or metastatic disease who have received at least two prior chemotherapeutic regimens for breast cancer, as follows: * At least...
Top 20 of 87 competitors
CR011-vcMMAE was studied for the treatment of breast cancer and for unresectable Stage III or Stage IV melanoma. It is an oncology therapeutic candidate developed by Celldex Therapeutics. Both indications were evaluated in early-stage clinical trials that have since been completed.
CR011-vcMMAE targets GPNMB, a protein also known as glycoprotein non-metastatic melanoma protein B. By binding to GPNMB, the agent is designed to deliver a cytotoxic payload to cells expressing this target. GPNMB is the molecular target of this investigational oncology therapy.
CR011-vcMMAE is being developed by Celldex Therapeutics, Inc., a biotechnology company whose common stock trades under the ticker symbol CLDX. Celldex conducted the clinical studies of CR011-vcMMAE in breast cancer and melanoma.
CR011-vcMMAE is in Phase 1 clinical development. It has been evaluated in Phase 1 trials for breast cancer and melanoma. The studies are completed, and no active trials are currently listed for this candidate.
CR011-vcMMAE has been studied in two completed clinical trials: NCT00704158, a Phase 1 study in locally advanced or metastatic breast cancer with 42 participants, and NCT00412828, a Phase 1/2 study in unresectable Stage III or Stage IV melanoma with 117 participants. Both trials were conducted in the United States.